These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17333104)

  • 21. A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Ruan CM; Zhou XB; Cao YL; Li S
    Biotechnol Lett; 2006 Jun; 28(12):863-8. PubMed ID: 16786270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells.
    Konrad D; Rudich A; Bilan PJ; Patel N; Richardson C; Witters LA; Klip A
    Diabetologia; 2005 May; 48(5):954-66. PubMed ID: 15834551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
    Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
    Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.
    Huang S; Ma S; Ning M; Yang W; Ye Y; Zhang L; Shen J; Leng Y
    Metabolism; 2019 Oct; 99():45-56. PubMed ID: 31295453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new, highly selective murine peroxisome proliferator-activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice.
    Ngala RA; Stocker CJ; Roy AG; Hislop D; Wargent E; Bell R; Hassall DG; Harling JD; Billin AN; Willson TM; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2011 May; 13(5):455-64. PubMed ID: 21272187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of medicinal plants for PPARα and PPARγ activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis.
    Yang MH; Avula B; Smillie T; Khan IA; Khan SI
    Planta Med; 2013 Aug; 79(12):1084-95. PubMed ID: 23877921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
    Coletta DK; Fernandez M; Cersosimo E; Gastaldelli A; Musi N; DeFronzo RA
    Diabet Med; 2015 May; 32(5):657-64. PubMed ID: 25484175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes.
    Shimaya A; Kurosaki E; Shioduka K; Nakano R; Shibasaki M; Shikama H
    Horm Metab Res; 1998 Sep; 30(9):543-8. PubMed ID: 9808320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gly-Ala-Gly-Val-Gly-Tyr, a novel synthetic peptide, improves glucose transport and exerts beneficial lipid metabolic effects in 3T3-L1 adipoctyes.
    Kim ED; Kim E; Lee JH; Hyun CK
    Eur J Pharmacol; 2011 Jan; 650(1):479-85. PubMed ID: 20951125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice.
    Seto SW; Lam TY; Leung GP; Au AL; Ngai SM; Chan SW; Kwan YW
    Eur J Pharmacol; 2007 Oct; 572(1):40-8. PubMed ID: 17603034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osthole inhibits inflammatory cytokine release through PPARα/γ-mediated mechanisms in LPS-stimulated 3T3-L1 adipocytes.
    Wang XL; Shang X; Cui Y; Zhao X; Zhang Y; Xie ML
    Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):185-92. PubMed ID: 25689951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
    Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
    Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
    Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation.
    Hontecillas R; O'Shea M; Einerhand A; Diguardo M; Bassaganya-Riera J
    J Am Coll Nutr; 2009 Apr; 28(2):184-95. PubMed ID: 19828904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.